Convalife Pharmaceutical

Convalife is a clinical-stage biopharmaceutical company based in Shanghai, China, specializing in the development of innovative therapies for oncology, virology, and age-related diseases. The company leverages its proprietary Right6D+AI technology platform to accelerate drug discovery and development, focusing on candidates with First-in-Class or Best-in-Class potential. Its portfolio includes HANNAIJIA (neratinib), which is approved in China for HER2-positive breast cancer, and CVL218 (mefuparib), a second-generation PARP inhibitor in clinical trials for various cancers and COVID-19. Convalife has established significant partnerships with companies like Henlius and Hutchmed, and has expanded its pipeline through strategic acquisitions, such as the global rights to the PI3K β/δ inhibitor CVL237. The company is currently advancing its pipeline toward international markets while maintaining a strong presence in the Greater China region.